Date: 2026-05-14 Price: 413.3p | Forward P/E: 13.5x | Graham Score: 3/7 (4/7 normalized) | Sector: UK Defense Services
QinetiQ reported a GBP 186M statutory net loss in FY2025 driven entirely by a one-time goodwill impairment (GBP 143.9M on US acquisitions FMI/MTEC and Avantus Federal, plus GBP 162M restructuring). The underlying business kept earning: underlying EPS 26.1p, operating margin 11.4% in UK/EMEA, and the dividend was GROWN +7% through the impairment year.
The market priced QinetiQ as if the impairment exposed structural decay. The data says otherwise: 12% order intake growth, GBP 5B backlog (record), LTPA contract extended to 2033 at GBP 1.54B (the UK MoD's mandatory test/trials/evaluation provider — a quasi-monopoly), and FY2026 guidance reiterated four times at 15-20% EPS growth.
At 413p, the forward P/E is 13.5x on FY2026 consensus 30.5p — the lowest in European defense. Graham break-even growth: 2.7%. The market requires barely any growth in perpetuity from a business with 89% H2 revenue cover.
This is "QinetiQ at 11.9x FY2027 EPS while sector peers trade at 25-35x." If the May 21 results confirm guidance, the re-rating is mechanical.
Sector-wide European defense pullback (March-May 2026). Ceasefire speculation + valuation reset took the MSCI Europe A&D Index -9.2% in March. QinetiQ dragged from 579p peak to 398p 52-week low on May 12 — -28.7% drawdown not driven by company-specific bad news. The selloff is pure sector rotation.
FY2026 preliminary results scheduled 2026-05-21 (7 days away). This is a binary catalyst. Revenue cover at H2 start was 89% — exceptionally high visibility. A miss would be hard to excuse. An in-line/beat would crystallize the 30.0-31.3p EPS guidance and trigger re-rating.
Dividend grown +7% through the loss year (8.85p FY2025 vs 8.25p FY2024). Management does not raise dividends on businesses they believe are structurally damaged. The interim FY2026 dividend (3.0p) was also +7.1%. The buyback program continues. These are the strongest possible signals from management to shareholders.
US restructuring showing early validation. US book-to-bill 1.5x in H1 FY2026 (recovery from FY2025 disaster). Federal IT business disposed entirely. Strategy refocused on maritime, sensors, space/missile defense — areas aligned with Trump administration priorities.
The GBP 143.9M US goodwill write-down breaks down approximately as:
Trigger events were specific and documentable:
Why I believe it's one-time:
Why caution remains:
The kitchen-sink interpretation is credible but not proven. If a second impairment arrives within 12 months, the thesis is dead.
European defense sector peer multiples (May 2026):
QinetiQ at forward 13.5x is 40-60% cheaper than peers. The discount is partially justified (smaller cap, US underperformance, impairment history) but not fully — especially given:
At 5% sustained growth (well below 15-20% FY2026 guidance), Graham IV on FY2026 EPS is 552p — implying +33% upside. At 7.5% growth, IV is 701p (+70%). The consensus PT of 545p prices the 5% growth scenario.
Binary event in 7 days. Cannot enter blind. FY2026 results on May 21 will move the stock 10-15% in either direction. Buying before would be speculation on direction, not Graham value.
US business is still at risk. 3.6% operating margin vs UK's 11.4%. The pivot to maritime/sensors/space is unproven at scale. Trump administration priorities can shift quarterly.
Residual goodwill GBP 325M in US CGU. A further impairment is possible if US restructuring stalls. This is the single biggest tail risk.
Brexit excludes QinetiQ from EU SAFE Fund (EUR 150B). Structural market access constraint. European continental defense spending is not directly addressable.
CFO has not bought at current price. Pre-results blackout explanation is credible, but absence of insider buying at 52-week lows is an AMBER signal.
UK Stamp Duty 0.5% adds friction on entry (GBP 2.50 per GBP 500 deployed).
GO conditions (all must be met):
NO-GO conditions (any one triggers):
If GO: deploy T1 (~95 shares ~EUR 480) at any price ≤450p. T2 of 25 shares at 380-400p on retest.
If NO-GO: skip and redeploy budget to AM.PA T3 or wait for IDR.MC Q2.
QinetiQ is the contrarian Graham play in European defense — a UK quality franchise temporarily depressed by a one-time accounting hit and sector-wide rotation. The break-even growth of 2.7% on forward EPS is extraordinarily conservative given LTPA, AUKUS, and SDR exposure.
But timing matters. The May 21 results are the entire trade. Buying today is a coin flip on a binary event. Buying on May 22 with confirmed guidance delivery is a Graham value entry at 13.5x forward P/E.
Recommendation: SUSPEND deployment until 2026-05-21 morning results. Reassess immediately post-release.